Hyalograft C: hyaluronan-based scaffolds in tissue-engineered cartilage.
Articular cartilage injuries have poor reparative capability and, if left untreated, may progress to osteo-arthritis. Unsatisfactory results with conventional treatment methods have prompted the development of innovative solutions including the use of cell transplantations, with or without a supporting scaffold. Tissue engineering combines cells, scaffolds and bio-active factors, which represents one of the most promising approaches for the restoration of damaged tissues. Available today, hyaluronan, also known as hyaluronic acid, is a natural glycosaminoglycan present in all soft tissues of higher organisms and in particularly high concentrations in the extracellular matrix of articular cartilage and in the mesenchyme during embryonic development in which it plays a number of biological functions, not only as a structural component but as an informational molecule as well. Moreover, hyaluronan can be manufactured in a variety of physical forms including hydrogels, sponges, fibres and fabrics allowing to develop a variety of hyaluronan-based scaffolds. This review will present both theoretical and experimental evidences that led to the development of Hyalograft C, an exploitation of hyaluronic acid technology and a tissue engineering approach for the resolution of articular cartilage defects.
Tognana
Enrico
E
Fidia Advanced Biopolymers, Abano Terme, Italy.
Borrione
Anna
A
De Luca
Claudio
C
Pavesio
Alessandra
A
D001672:Biocompatible Materials; D002358:Cartilage, Articular / Q000293:injuries* / Q000601:surgery; D019902:Chondrocytes / Q000637:transplantation; D006801:Humans; D006820:Hyaluronic Acid; D023822:Tissue Engineering
D001672:Biocompatible Materials; D006820:Hyaluronic Acid